Followers | 183 |
Posts | 25188 |
Boards Moderated | 14 |
Alias Born | 04/03/2002 |
Wednesday, March 15, 2017 11:17:40 AM
- Clinical Data from Multiple Phase 2 Development Programs Expected in 2017 -
SAN DIEGO, March 14, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2016.
"We are very pleased with our progress in 2016 as we have positioned the Company to deliver results on multiple Phase 2 programs in 2017. In the last nine months since the arrival of the new management team, we prioritized our Phase 2 programs; strengthened our board and team to support our strategy; implemented cost reduction measures; renegotiated our agreement with Eisai; and took a methodical approach to maximizing the value of our assets," said Amit Munshi, Arena's President and CEO.
As previously disclosed, in February 2017, Arena appointed Jayson Dallas, M.D., Oliver Fetzer, Ph.D., and Garry A. Neil, M.D. as independent directors to the Company's Board of Directors.
"This year we expect to report results from all three of our proprietary Phase 2 programs, beginning with ralinepag in mid-year for pulmonary arterial hypertension," Mr. Munshi stated. "For etrasimod, we remain focused on maximizing the broad clinical utility of this compound in a time and cost effective manner. We are pleased to have initiated Phase 2 trials in both dermatologic extraintestinal manifestations in inflammatory bowel disease patients and pyoderma gangrenosum. We also plan to initiate a study in primary biliary cholangitis this year. Additionally, we have made important adjustments to the Phase 2 ulcerative colitis trial to ensure a robust data readout by year-end 2017."
Pipeline Update
Ralinepag – oral, selective IP receptor agonist targeting the prostacyclin pathway for the potential treatment of pulmonary arterial hypertension (PAH)
Phase 2 trial in PAH Enrollment of the Phase 2 trial in pulmonary arterial hypertension was completed in December 2016 Data readout expected in mid-year 2017
Phase 1 pharmacokinetic and pharmacodynamic trial comparing current twice-daily formulation with a new once-daily formulation in healthy volunteers Trial initiated in March 2017 Data readout expected mid-year 2017
Etrasimod – orally available next generation sphingosine-1-phosphate (S1P) receptor modulator for the potential treatment of a number of autoimmune diseases
Phase 2 trial in ulcerative colitis (UC) Implementing protocol updates to the OASIS program that maintain study conduct, integrity, and patient safety; further the probability of a successful trial; and facilitate expected data readout in 2017
Phase 2 trial in dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD) Trial initiated in March 2017
Phase 2 trial in pyoderma gangrenosum (PG) Trial initiated in March 2017
Phase 2 trial in primary biliary cholangitis (PBC) Intend to initiate clinical study in 2017
APD371 – orally available full agonist of the cannabinoid-2, receptor for the potential treatment of visceral pain, specifically pain associated with Crohn's disease
Phase 2 trial in pain associated with Crohn's disease Currently incorporating feedback related to study design and conduct into the clinical protocol design and selecting sites
Collaborations Update
Axovant On February 13, 2017, Axovant announced preliminary results from the planned interim analysis of the first 11 patients to complete its Phase 2 study of nelotanserin in Lewy body dementia patients. Axovant has stated plans to initiate a Phase 3 in the second half of 2017
Eisai On December 28, 2016, Arena and Eisai Co., Ltd. and Eisai Inc. (collectively, "Eisai") amended and replaced the BELVIQ® (lorcaserin HCl) marketing and supply agreement. Under the revised agreements, Eisai acquired global commercialization rights to BELVIQ and is responsible for all lorcaserin development expenses going forward. The financial terms of the revised agreement are expected to provide Arena with $23 million of cash payments, including $10 million received in the fourth quarter, and over $80 million of potential cost relief on lorcaserin development obligations in the next three years. In addition, Arena will continue to be eligible to receive royalty payments on net sales of BELVIQ and participate in the upside potential of lorcaserin from additional geographies and clinical trials such as the ongoing cardiovascular outcomes trial, CAMELLIA As a result of the Eisai transaction, a significant amount of non-cash items were recognized in the 2016 financial statements
Financial Update
Fourth Quarter 2016 Financial Results
Revenues totaled $85.4 million, including $15.2 million in net product sales of BELVIQ, $1.3 million in milestone payments earned from Eisai and Ildong for BELVIQ, and $66.1 million of revenue associated with upfront BELVIQ payments
Research and development expenses totaled $11.9 million
General and administrative expenses totaled $7.3 million
Impairment of assets totaled $21.8 million
Net income was $38.3 million or $0.16 per share
Full Year 2016 Financial Results
Revenues totaled $124.0 million, including $26.3 million in net product sales of BELVIQ, $12.3 million of milestone payments earned from Eisai and Ildong for BELVIQ, and $72.1 million of revenue associated with upfront BELVIQ payments
Research and development expenses totaled $66.4 million
General and administrative expenses totaled $31.2 million
Restructuring charges totaled $6.3 million
Impairment of assets totaled $21.8 million
Net loss was $22.9 million, or $0.09 per share
At December 31, 2016, cash and cash equivalents totaled $90.7 million and approximately 243 million shares of Arena common stock were outstanding.
2017 Financial Guidance
The Company expects the full year 2017 net cash used in operating and investing activities to be $80 to $100 million, assuming no additional partnerships and no adjustment to our development plans.
Conference Call & Webcast Information
The Company will host a conference call and live webcast with the investment community today, Tuesday, March 14, 2017, at 4:30 p.m. ET to discuss the financial results and provide a corporate update.
When: March 14, 2017, 4:30 p.m. ET
Dial-in: (877) 643-7155 (United States) or (914) 495-8552 (International)
Conference ID: 80816089
Please join the conference call at least 10 minutes early to register.
You can access the live webcast under the investor relations section of Arena's website at: www.arenapharm.com. A replay of the conference call will be archived under the investor relations section of Arena's website for 30 days shortly after the call.
About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Our three most advanced investigational clinical programs are ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH), etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune indications, and APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about expected results, data readouts and timing relating to ongoing clinical trials; expected payments and potential cost relief under the revised agreements with Eisai; financial guidance for 2017; and Arena's focus, goals, strategy and clinical programs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that we may need additional funds to advance all of our programs, and you and others may not agree with the manner we allocate our resources; risks related to developing and commercializing drugs; cash and revenues generated from BELVIQ and our revised agreements with Eisai; the risk that Arena's revenues are based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of research, development and regulatory review is uncertain, and our drug candidates may not advance in development or be approved for marketing; government and third-party payor actions, including relating to reimbursement and pricing; risks related to relying on collaborative arrangements; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; Arena's and third parties' intellectual property rights; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Contact:
Kevin R. Lind, Chief Financial Officer
klind@arenapharm.com
858.210.3636
(Tables Follow)
Arena Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
Three months ended
Year ended
December 31,
December 31,
2016
2015
2016
2015
(unaudited)
Revenues
Net product sales
$ 15,245
$ 3,939
$ 26,349
$ 19,726
Other Eisai collaboration revenue
61,546
2,091
79,701
9,505
Other collaboration revenue
7,730
670
13,796
4,845
Toll manufacturing
853
1,051
4,129
4,250
Total revenues
85,374
7,751
123,975
38,326
Operating Costs & Expenses
Cost of product sales
5,136
2,461
9,297
8,590
Cost of toll manufacturing
1,168
787
6,044
4,585
Research & development
11,911
20,170
66,425
88,411
General & administrative
7,264
9,655
31,243
35,966
Restructuring charges
0
3,972
6,346
3,972
Impairment of long-living assets
21,766
0
21,766
0
Total operating costs & expenses
47,245
37,045
141,121
141,524
Interest & Other Income (Expense)
Interest income
43
53
290
158
Interest expense
(1,605)
(1,695)
(6,512)
(6,828)
Gain from valuation of derivative liabilities
0
0
0
474
Other
1,747
477
472
1,415
Total interest & other income (expense), net
185
(1,165)
(5,750)
(4,781)
Net income (loss)
38,314
(30,459)
(22,896)
(107,979)
Less net loss attributable to noncontrolling interest in consolidated variable interest entity
258
0
380
0
Net income (loss) attributable to stockholders of Arena
$ 38,572
$ (30,459)
$ (22,516)
$ (107,979)
Net income(loss) attributable to stockholders of Arena per share:
Basic
$ 0.16
$ (0.13)
$ (0.09)
$ (0.45)
Diluted
$ 0.16
$ (0.13)
$ (0.09)
$ (0.45)
Shares used in calculating net loss attributable to stockholders of Arena per share:
Basic
243,325
242,566
243,133
240,671
Diluted
243,495
242,566
243,133
240,671
Arena Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheet Data
(In thousands)
December 31, 2016
December 31, 2015
1
1
Assets
Cash & cash equivalents
$ 90,712
$ 156,184
Accounts receivable
20,162
4,934
Inventory
6,708
9,502
Prepaid expenses & other current assets
2,307
4,218
Land, property & equipment, net
43,828
71,828
Intangibles & other non-current assets
5,293
10,126
Total assets
$ 169,010
$ 256,792
Liabilities & Equity
Accounts payable & accrued liabilities
$ 25,073
$ 25,493
Total deferred revenues
37,455
109,042
Total lease financing obligations & other long-term liabilities
66,087
68,715
Total equity
40,395
53,542
Total liabilities & equity
$ 169,010
$ 256,792
1 The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.
http://photos.prnewswire.com/prnthumb/20161107/436843LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2016-financial-results-300423507.html
SOURCE Arena Pharmaceuticals, Inc.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM